Registered entities
G1 THERAPEUTICS, INC
Reg. No. 263648180United States
G1 THERAPEUTICS, INC.
Reg. No. 1560241United States
G1 Therapeutics, Inc.
Reg. No. 10172698United States
G1 Therapeutics, Inc.
Reg. No. 26-3648180Belgium
Innovation
42 patent families (22 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 11,345 times.
| Year | Filings |
|---|---|
| 2014 | 5 |
| 2015 | 6 |
| 2016 | 9 |
| 2017 | 10 |
| 2018 | 16 |
| 2019 | 24 |
| 2020 | 25 |
| 2021 | 21 |
| 2022 | 17 |
| 2023 | 16 |
| 2024 | 11 |
| 2025 | 6 |
Investor mix
18 investors on record; lead investors include MedImmune Ventures, Hatteras Venture Partners, Eshelman Ventures, RA Capital Management; 2 have since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 9 | 50% |
| Private equity | 2 | 11% |
| Accelerator & incubator | 1 | 6% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 5 | 28% |